Returns Chart

Returns Chart

Key Stats

Net Expense Ratio Total Assets Under Management Weighted Average Dividend Yield Turnover Ratio (Generic)
0.72% 1.286B 0.91% 59.00%
1 Year Fund Level Flows 1 Year Total Returns (Daily) Annualized Total Returns Since Inception (Daily) Max Drawdown (Since Inception)
-138.74M 11.42%

Basic Info

Investment Strategy
The Fund seeks long-term growth of capital. The Fund invests, under normal circumstances, at least 80% of its net assets in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities.
General
Security Type Mutual Fund
Equity Style Multi Cap Growth
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Invesco
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Net Fund Flows Versus Peer Group

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: 74
-258.69M Peer Group Low
40.23M Peer Group High
1 Year
% Rank: 72
-138.74M
-4.152B Peer Group Low
118.44M Peer Group High
3 Months
% Rank: 78
-781.12M Peer Group Low
95.26M Peer Group High
3 Years
% Rank: 54
-15.96B Peer Group Low
379.82M Peer Group High
6 Months
% Rank: 68
-1.898B Peer Group Low
239.17M Peer Group High
5 Years
% Rank: 69
-21.94B Peer Group Low
451.06M Peer Group High
YTD
% Rank: 74
-3.299B Peer Group Low
1.026B Peer Group High
10 Years
% Rank: 47
-42.70B Peer Group Low
814.82M Peer Group High
Date Unavailable

Performance Versus Peer Group

 
20%
15%
10%
5%
0
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (NAV)
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
Peer Group Rtn. (NAV)
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
% Rank in Peer Group (NAV)
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
View Performance Versus Peer Group
Start Trial

Annual Total Returns Versus Peers

Loading chart...
Name
2019
2020
2021
2022
2023
2024
2025
YTD
32.39%
14.80%
12.56%
-13.22%
3.42%
4.30%
15.88%
11.90%
27.67%
15.90%
21.82%
-18.14%
23.79%
18.67%
21.09%
8.92%
29.92%
15.64%
19.12%
-4.93%
8.75%
1.01%
14.87%
13.19%
17.71%
40.72%
5.66%
-10.65%
11.97%
8.12%
18.89%
12.47%
25.64%
12.73%
21.83%
-9.72%
5.43%
3.21%
10.03%
11.90%
33.65%
22.89%
10.24%
-11.50%
4.02%
0.26%
15.91%
16.63%
As of November 17, 2026.

Fundamentals

General
Distribution Yield --
Dividend Yield TTM (11-16-26) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings 10
Stock
Weighted Average PE Ratio 38.46
Weighted Average Price to Sales Ratio 9.665
Weighted Average Price to Book Ratio 11.05
Weighted Median ROE 304.0%
Weighted Median ROA 2.76%
Return on Investment (TTM) 4.92%
Earning Yield 0.0298
LT Debt / Shareholders Equity 1.671
Number of Equity Holdings 10
As of September 30, 2026

Growth Metrics

EPS Growth (1Y) 30.02%
EPS Growth (3Y) 17.01%
EPS Growth (5Y) 15.58%
Sales Growth (1Y) 23.24%
Sales Growth (3Y) 19.83%
Sales Growth (5Y) 18.12%
Sales per Share Growth (1Y) 124.7%
Sales per Share Growth (3Y) 19.53%
Operating Cash Flow - Growth Rate (3Y) 9.15%
As of September 30, 2026

Asset Allocation

As of September 30, 2026.
Type % Net
Cash 0.55%
Stock 98.71%
Bond 0.74%
Convertible 0.00%
Preferred 0.00%
Other 0.00%
View Asset Allocation
Start Trial

Top 10 Holdings

Name % Weight Price % Change
Eli Lilly & Co. 12.12% 1431.67 -0.82%
Johnson & Johnson 6.68% 282.55 -1.12%
UnitedHealth Group, Inc. 4.79% 412.02 1.12%
AbbVie, Inc. 4.47% 294.55 -0.16%
Merck & Co., Inc. 4.44% 144.46 -2.23%
Gilead Sciences, Inc. 3.75% 167.58 -0.30%
Thermo Fisher Scientific, Inc. 3.21% 691.33 -1.27%
Vertex Pharmaceuticals, Inc. 2.56% 537.79 -0.15%
Royalty Pharma Plc 2.32% 68.52 -1.13%
Cardinal Health, Inc. 2.16% 283.85 0.98%

Fees & Availability

Fees
Actual 12B-1 Fee --
Actual Management Fee 0.64%
Administration Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
General Availability
Available for Insurance Product No
Available for RRSP No
Purchase Details
Open to New Investors Yes
Minimum Initial Investment 1.00M None
Minimum Subsequent Investment 0.00 None

TTM Distributions

View TTM Distributions. Upgrade now.
Type Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct
Qualified Income
-- -- -- -- -- -- -- -- -- -- -- --
Normal
-- -- -- -- -- -- -- -- -- -- -- --
Qualified
-- -- -- -- -- -- -- -- -- -- -- --
LT Cap Gains
-- -- -- -- -- -- -- -- -- -- -- --
Ordinary Income
-- -- -- -- -- -- -- -- -- -- -- --
Non-Qual
-- -- -- -- -- -- -- -- -- -- -- --
ST Cap Gains
-- -- -- -- -- -- -- -- -- -- -- --
Interest
-- -- -- -- -- -- -- -- -- -- -- --
Tax-Exempt
-- -- -- -- -- -- -- -- -- -- -- --
ROC
-- -- -- -- -- -- -- -- -- -- -- --
Other
-- -- -- -- -- -- -- -- -- -- -- --
Total
-- -- -- -- -- -- -- -- -- -- -- --
As of October 31, 2026.

Basic Info

Investment Strategy
The Fund seeks long-term growth of capital. The Fund invests, under normal circumstances, at least 80% of its net assets in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities.
General
Security Type Mutual Fund
Equity Style Multi Cap Growth
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Invesco
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Fundamentals

General
Distribution Yield --
Dividend Yield TTM (11-16-26) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings 10
Stock
Weighted Average PE Ratio 38.46
Weighted Average Price to Sales Ratio 9.665
Weighted Average Price to Book Ratio 11.05
Weighted Median ROE 304.0%
Weighted Median ROA 2.76%
Return on Investment (TTM) 4.92%
Earning Yield 0.0298
LT Debt / Shareholders Equity 1.671
Number of Equity Holdings 10
As of September 30, 2026

Growth Metrics

EPS Growth (1Y) 30.02%
EPS Growth (3Y) 17.01%
EPS Growth (5Y) 15.58%
Sales Growth (1Y) 23.24%
Sales Growth (3Y) 19.83%
Sales Growth (5Y) 18.12%
Sales per Share Growth (1Y) 124.7%
Sales per Share Growth (3Y) 19.53%
Operating Cash Flow - Growth Rate (3Y) 9.15%
As of September 30, 2026

Fund Details

Key Dates
Inception Date 4/4/2017
Last Annual Report Date 10/31/2025
Last Prospectus Date 2/27/2026
Share Classes
GGHCX A
GGHYX Inst
GTHCX C
GTHIX Inv
GTHRX Retirement
Attributes
Index Fund --
Inverse Fund No
Leveraged Fund --
Fund of Funds No
Currency Hedged Fund --
Socially Responsible Fund No

Top Portfolio Holders

Name % Weight
Portfolio A 5.00%
Portfolio B 3.50%
Portfolio C 2.25%
View Top Portfolio Holders
Start Trial

Excel Add-In Codes

Name: =YCI("M:GGHSX", "name")
Broad Asset Class: =YCI("M:GGHSX", "broad_asset_class")
Broad Category: =YCI("M:GGHSX", "broad_category_group")
Prospectus Objective: =YCI("M:GGHSX", "prospectus_objective")
To find the codes for any of our securities and financial metrics, see our Complete Excel Reference.
View Excel Add-In Codes
Start Trial